Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine in Bipolar Depression (BOLDER II)
NCT00083954Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quetiapine in bipolar disorder (BD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Jun 2004; status: completed.
02
Drugs
quetiapine
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00083954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083954.